Pfizer initiates Phase III programme for Spark’s haemophilia B gene therapy

07:00 EDT 20 Jul 2018 | EPM Magazine

Pfizer and Spark Therapeutics have announced that the Phase III programme for the investigational haemophilia B gene therapy is to be initiated by Pfizer.

More From BioPortfolio on "Pfizer initiates Phase III programme for Spark’s haemophilia B gene therapy"